(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 April 2012 (19.04.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/050921 A3

(51) International Patent Classification:
C07K 14/47 (2006.01) *A61P 25/00* (2006.01)
C07K 19/00 (2006.01) *A61P 35/00* (2006.01)
A61K 38/17 (2006.01)

(21) International Application Number:
PCT/US2011/053764

(22) International Filing Date:
28 September 2011 (28.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/387,439 28 September 2010 (28.09.2010) US

(71) Applicant *(for all designated States except US)*: **NONO, INC.** [CA/CA]; 88 Strath Avenue, Toronto, Ontario M8X 1R5 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TYMIANSKI, Michael** [CA/CA]; 175 Dawlish Avenue, Toronto, Ontario M4N 1H6 (CA). **LI, Rongwen** [CN/CA]; 904 Kennedy Road, Toronto, Ontario M1K 2E8 (CA). **GARMAN, Johathan David** [US/CA]; 148 Lawrie Road, Thornhill, Ontario L4J 8N1 (CA).

(74) Agents: **LIEBESCHUETZ, Joe** et al.; Alston & Bird LLP, Bank of America Plaza 101 South Tryon Street, Suite 4000, Charlotte, North Carolina 28280-4000 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

[Continued on next page]

(54) **Title**: ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE




Figure 18

(57) **Abstract**: The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src. Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.

WO 2012/050921 A3

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
5 July 2012